|
|
|
|
|
19.10.26 - 10:33
|
Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer (Business Wire)
|
|
|
Dr. Weber, an otologist and neurotologist who led the clinical development of the first FDA-approved gene therapy for genetic hearing loss, joins as SENS-601 advances into the clinic
MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR001401A9Z0 – ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company that develops novel therapies to restore hearing and to treat and prevent hearing loss disorders, today announced the appointment of Peter Weber, MD, MBA, as Chief Medical Officer, effective November 2, 2026.
Dr. Weber is an otologist and neurotologist with more than two decades of clinical and industry leadership in hearing loss. Dr. Weber possesses deep expertise in rare genetic ear disorders and is one of the few physicians to have led the clinical development of gene therapies for genetic hearing loss.
Earlier, as Chief Medical Officer of Decibel Therapeutics, and later as Senior Medical Consultant to Regeneron, Dr. Weber guided several monogeni...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
